MLD10 for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus
Status:
Not yet recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
To determine the effect of MLD10 (magnesium L-lactate dihydrate extended-release caplets) 10
mEq BID on serum magnesium in Type 2 diabetic patients with hypomagnesemia.